Cantor Fitzgerald initiated coverage on Compass Therapeutics
$CMPX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald initiated coverage of Compass Therapeutics with a rating of Overweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2026 | Outperform | William Blair | |
| 12/3/2025 | $10.00 | Mkt Outperform | Citizens JMP |
| 12/3/2025 | $10.00 | Buy | Canaccord Genuity |
| 12/3/2025 | Overweight | Cantor Fitzgerald | |
| 7/1/2025 | $9.00 | Outperform | Raymond James |
| 4/2/2025 | $6.00 | Market Perform → Outperform | Leerink Partners |
| 2/24/2025 | $12.00 | Buy | Guggenheim |
| 2/19/2025 | $12.00 | Overweight | Piper Sandler |
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under the Company's 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted non-qualified stock options to purchase 1,000,000 shares of common stock to its newly appointed Chief Commercial Officer, Arjun Prasad, and also granted non-qualified stock options to purchase 1,000,000 shares of common stock to its newly appoi
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. "We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "Arjun's world-class expertise in on
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. Presentation DetailsDate: Wednesday, January 14, 2026 Time: 7:30 AM PT Webcast Link: cmpx.info/jpmorgan Virtual/Replay availability: The presentation will be archived on Compass' Events page. Investors interested in scheduling one-on-one meetings with Compass on January 14, 2026 should contact their J.P. Morgan representative. Compass will also host investor meetings as part of the
William Blair initiated coverage of Compass Therapeutics with a rating of Outperform
Citizens JMP initiated coverage of Compass Therapeutics with a rating of Mkt Outperform and set a new price target of $10.00
Canaccord Genuity initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $10.00
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
EFFECT - Compass Therapeutics, Inc. (0001738021) (Filer)
8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
DEL AM - Compass Therapeutics, Inc. (0001738021) (Filer)
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026. "We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "Arjun's world-class expertise in on
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available
In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in patients treated in the post-checkpoint inhibitor setting, two deep and confirmed partial responses have been observed to date. A patient with non-small cell lung cancer had a 100% reduction in target le
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Call Details: Date: Monday, August 11, 2025 Time: 8:00 AM ET Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1727543&tp_key=955a2c2f4d Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Co
Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details: Date: May 04, 2022 Time: 8:00 a.m. ET Webcast: Registration Link Replay availability: A replay will be available on the Compass website for 6 months. Abo
SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)
SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)